Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes

Figures & data

Figure 1 Combined positive score (CPS) of PD-L1 expression defined by (total number of stained tumor cells and immune cells divided by number of all viable tumor cells) × 100; tumor proportion score (TPS) of PD-L1 expression defined by percentage of stained tumor cells; immune cell (IC) PDL1 expression defined by percentage of stained immune cells. Arrows indicate PD-L1-positive cells accounted for in each scoring criterion’s calculations to describe PD-L1 expression. Reprinted from Sajjadi E, Venetis K, Scatena C, Fusco N. Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? Ecancermedicalscience. 2020;14. Creative Commons.⁷

Sajjadi E, Venetis K, Scatena C, Fusco N. Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? Ecancermedicalscience. 2020;14. doi:10.3332/ECANCER.2020.1150

 PubMed Web of Science ®Google Scholar